entertainment -WSS

entertainment

author：focus 2025-09-30 21:07:25 - browse：153

Several amyloid plaques forming between neurons in a brain — Amyloid plaques forming between neurons. Adobe

The Food and Drug Administration on Thursday granted full approval to the first therapy for Alzheimer’s disease clearly shown to slow the cognitive decline associated with the disease — a milestone in treatment, even if the benefits are modest.

The drug, called Leqembi, was developed by Eisai, the Japanese pharmaceutical company, and sold in partnership with Biogen. It previously secured conditional approval in January. The FDA’s decision will broaden patient access to the drug under the Medicare program and is likely to boost sales, even as Leqembi’s benefits and safety risks continue to be a source of debate.

Leqembi’s full, or traditional, approval was supported by results of a large clinical trial in which the drug slowed the rate of cognitive and functional decline by 27% compared to a placebo. Leqembi also beat placebo on a series of secondary measures of Alzheimer’s, and it had a dramatic effect on clearing toxic brain plaques called beta-amyloid, which play a role in the progression of the disease.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： After traumatic brain injury, life support decisions can use more time

leisure time

WSS

Mega Millions pot grows to $1.25 billion after no winner

Canadian Prime Minister Justin Trudeau separating from wife, Sophie

NIH launches clinical trials and new research office for long Covid

H5N1 bird flu virus started spreading in cows in Texas in December

H5N1 bird flu virus started spreading in cows in Texas in December

Vertex non

leisure time

entertainment

Wikipedia

Hepatitis C has a cure — but many Americans still lack access to it

Pence says 'crackpot lawyers' told Trump what he wanted to hear

Novavax promises a turnaround & Lilly roils the obesity market

Trump indictment: Who are the 'co

Tori Bowie and the unacceptable rates of Black maternal death

Lawsuit alleges UnitedHealth Group unit illegally denied claims

Moonlake's readout produced a cash windfall. Risks remain

Cancer researcher Catriona Jamieson is sending tumors into space

The high cost of giving birth even with insurance

Physician groups backed by private equity giant lobby on mergers

entertainment

Tire on Delta flight pops while landing in Atlanta, 1 person injured, airline says

Bird flu outbreak in cows is latest avian flu curveball

The high personal cost of affirmative action for Black doctors

New safety details link Apellis eye drug to rare cases of blindness

Micronoma's microbiome cancer diagnostic approach under fire

Breakthrough Alzheimer’s drugs are inaccessible in rural states

knowledge

leisure time

focus

focus